+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurodegenerative Drugs: Global Strategic Business Report

  • PDF Icon

    Report

  • 344 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227799

Global Neurodegenerative Drugs Market to Reach $57.3 Billion by 2030

The global market for Neurodegenerative Drugs estimated at US$40.6 Billion in the year 2022, is projected to reach a revised size of US$57.3 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030. Multiple Sclerosis, one of the segments analyzed in the report, is projected to record a 4.7% CAGR and reach US$38.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Parkinson`s segment is readjusted to a revised 3.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $11.1 Billion, While China is Forecast to Grow at 7.5% CAGR

The Neurodegenerative Drugs market in the U.S. is estimated at US$11.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$12.1 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.3% and 4.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.7 Billion by the year 2030.

Select Competitors (Total 163 Featured) -

  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Neurodegenerative Drugs

What is the estimated value of the Global Market for Neurodegenerative Drugs?

The Global Market for Neurodegenerative Drugs was estimated to be valued at $40.6 Billion in 2022.

What is the growth rate of the Global Market for Neurodegenerative Drugs?

The growth rate of the Global Market for Neurodegenerative Drugs is 4.4%, with an estimated value of $57.3 Billion by 2030.

What is the forecasted size of the Global Market for Neurodegenerative Drugs?

The Global Market for Neurodegenerative Drugs is estimated to be worth $57.3 Billion by 2030.

Who are the key companies in the Global Market for Neurodegenerative Drugs?

Key companies in the Global Market for Neurodegenerative Drugs include Biogen, Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Merck KGaA and Mitsubishi Tanabe Pharma Corporation.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Neurodegenerative Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Parkinson`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for Alzheimer`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy (SMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Spinal Muscular Atrophy (SMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for Spinal Muscular Atrophy (SMA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 18: World 18-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 19: World Neurodegenerative Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 22: USA 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 25: Canada 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
JAPAN
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 26: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Japan Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 28: Japan 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
CHINA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 29: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: China Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 31: China 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
EUROPE
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 32: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 34: Europe 18-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
  • Table 35: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 37: Europe 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
FRANCE
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 38: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: France Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 40: France 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
GERMANY
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 41: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Germany Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 43: Germany 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
ITALY
  • Table 44: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Italy Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 46: Italy 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
UNITED KINGDOM
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 47: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: UK Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 49: UK 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
SPAIN
  • Table 50: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Spain Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 52: Spain 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
RUSSIA
  • Table 53: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: Russia Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 55: Russia 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
REST OF EUROPE
  • Table 56: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: Rest of Europe Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 58: Rest of Europe 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
ASIA-PACIFIC
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 61: Asia-Pacific 18-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Asia-Pacific Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 64: Asia-Pacific 18-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2012, 2023 & 2030
AUSTRALIA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA